Lucent Diagnostics

Executive Summary

Lucent Diagnostics, a brand under Quanterix, is advancing Alzheimer's disease diagnostics through its ultra-sensitive, blood-based biomarker testing platform powered by Simoa® technology. By detecting single molecules of biomarkers in blood, Lucent offers a non-invasive, scalable alternative to traditional cerebrospinal fluid (CSF) analysis and PET imaging, enabling earlier and more accurate detection of Alzheimer's pathology. The company's focus on high-precision, low-volume blood tests positions it to address the growing demand for accessible, cost-effective screening tools in the neurodegenerative disease space, particularly as disease-modifying therapies emerge and require early diagnosis. With the Alzheimer's diagnostics market expanding rapidly due to an aging population and advances in therapeutic interventions, Lucent Diagnostics is strategically positioned to capture significant market share. The company's technology has already demonstrated strong performance in clinical studies, and ongoing efforts aim to secure regulatory clearances and commercial partnerships. Key upcoming milestones include the potential FDA 510(k) clearance for its lead blood test, release of pivotal validation data, and expansion of its test menu to cover additional neurodegenerative indications. These catalysts could drive adoption among healthcare providers and payers, potentially establishing Lucent as a leader in the blood-based Alzheimer's diagnostics segment.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Alzheimer's Blood Test70% success
• Q2 2026Publication of Pivotal Clinical Validation Study80% success
• Q4 2026Commercial Partnership with Major Health System60% success